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Abstract: Candida albicans is part of the normal microbiota in most healthy individuals. 
However, it can cause opportunistic infections if host defenses are breached, with symptoms 
ranging from superficial lesions to severe systemic disease. The study of rare congenital 
defects in patients with chronic mucocutaneous candidiasis led to the identification of 
interleukin-17 (IL-17) as a key factor in host defense against mucosal fungal infection. 
Experimental infections in mice confirmed the critical role of IL-17 in mucocutaneous 
immunity against C. albicans. Research on mouse models has also contributed importantly 
to our current understanding of the regulation of IL-17 production by different cellular 
sources and its effector functions in distinct tissues. In this review, we highlight recent 
findings on IL-17-mediated immunity against C. albicans in mouse and man. 
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1. Introduction 
Candida spp. are frequently found in the human microflora. They colonize the oral, intestinal and 
vaginal mucosa, as well as the skin of healthy individuals [1]. They shape microbial communities in 
these compartments and interact with immune cells for the development and homeostasis of the immune 
system. However, many Candida spp. act also as opportunistic pathogens and can cause a wide range of 
fungal diseases [2]. Of all Candida species, C. albicans is among the most prevalent and most studied 
ones. It can cause superficial infections of the skin and the oral and vaginal mucosa [3], as well as more 
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severe systemic infections, which are associated with a high degree of mortality and morbidity in those 
who survive [4,5]. The fungal pathogenicity depends on the host’s immune status, and disease symptoms 
arise primarily in immunocompromised individuals [6]; however, C. albicans can also cause disease in 
otherwise healthy individuals, such as is the case, for instance, for vulvovaginal candidiasis [7]. 
The conditions predisposing for candidemia are linked to modern medical treatments and include 
chemotherapy, immunosuppressive therapy, deep tissue surgery or the insertion of central venous 
catheters [8,9]. Mucocutaneous candidiasis, on the other hand, is a frequent complication in AIDS 
patients displaying low CD4+ T cell counts as a consequence of the viral infection and in severe 
combined immunodeficiency (SCID) patients with more general T cell defects [10]. More recently, 
congenital defects in genes linked to the interleukin 17 (IL-17) pathway have also been associated with 
mucocutaneous candidiasis [11]. Primary immunodeficiencies have thus emerged as an important risk 
factor for opportunistic (fungal) infections [12]. In this review, we focus on IL-17-mediated antifungal 
immunity and discuss the current understanding of the regulation of IL-17 production and the IL-17-mediated 
effector functions in response to C. albicans. The main focus is put on mucocutaneous C. albicans 
infections, but we also discuss the role of IL-17 in the context of vulvovaginal candidiasis (VVC) and 
systemic candidiasis. 
2. IL-17 Family of Cytokines 
The first gene of the IL-17 cytokine family was cloned in 1993 [13]. Since then, six IL-17 cytokines 
(IL-17 A to F) have been identified in human and mouse [14]. IL-17A and IL-17F share the highest 
amino acid sequence homology. They can form homo- and hetero-dimers, and they are often found to 
be co-expressed. Besides their protective role against C. albicans, IL-17A and IL-17F have gained much 
attention due to their capacity to promote autoinflammatory diseases, such as psoriasis and rheumatoid 
arthritis, and targeting the IL-17 pathway has become a promising approach in treating some of these 
conditions [15]. IL-17C is functionally related to IL-17A and IL-17F, while IL-17E (also called IL-25) 
is associated with type 2 immunity [14]. Other IL-17 family members remain ill-defined. 
The family of IL-17 receptors comprises five structurally-related proteins (IL-17RA to IL-17RE) [14]. 
The biological activity of IL-17A, C, E and F depends on IL-17RA, which can pair with any of the other 
four receptor subunits. While IL-17RC plays a requisite role for the function of IL-17A and F homo- 
and hetero-dimers, IL-17C and IL-17E (IL-25) signal via complexes composed of IL-17RA and  
IL-17RE or IL-17RA and IL-17RB, respectively. The orphan receptor subunit IL-17RD was suggested 
to modulate IL-17A signaling [16]. 
In contrast to most other cytokines, which trigger JAK-STAT signaling cascades, IL-17 receptors 
function via a distinct pathway that depends on Act1 (also referred to as CIKS) and activates NF-κB and 
MAP kinases [14] for the induction of pro-inflammatory mediators. An alternative pathway that also 
involves MAP kinases affects target gene expression by controlling the stability of mRNA transcripts [14]. 
Due to these unique features and the sparse homology to other known cytokines or receptors, the IL-17 
cytokine family is thought to represent a distinct ligand-receptor signaling system that has been well 
conserved throughout evolution. IL-17 homologs have been cloned and characterized from many 
different vertebrates [17–24], but also from invertebrates, such as sea quirt, sea urchin and mollusks [25–27]. 
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In humans, rare mutations in the genes encoding IL-17F, IL-17RA, IL-17RC, RORc and Act1 are strongly 
associated with chronic mucocutaneous candidiasis (CMC) [28–31]. In addition, mutations in STAT3 and 
DOCK8 and gain-of-function mutations in STAT1, which result in the absence of IL-17-secreting Th17, 
also underlie CMC [32–40]. Moreover, defects in CARD9, an adaptor protein of the innate pathway 
coupling fungal recognition to Th17 induction, is also associated with an increased susceptibility to 
Candida [41–44]. In most cases, these patients are affected by isolated CMC. Susceptibility to such a 
narrow spectrum of infections is surprising and indicates that the IL-17 pathway and, in particular, IL-17A 
and IL-17F play a particular and non-redundant role in host defense against mucocutaneous infections 
with C. albicans. In line with the critical role of IL-17 in antifungal immunity, fungal evasion strategies 
have been proposed [45]. However, the mechanisms of IL-17-mediated protection remain unclear. 
Studies with experimental models of cutaneous and oropharyngeal C. albicans infections over the last 
few years have contributed to a better understanding of the regulation and function of IL-17 immunity 
against C. albicans. Besides C. albicans, non-albicans species of Candida, in particular C. glabrata, can 
also affect patients with CMC. However, the role of IL-17 immunity in host defense against this fungus 
remains largely unexplored. In the following, we will reflect on some of the recent advancements in the 
field, most of which have been gained from animal models. 
3. Cellular Sources of IL-17 during CMC 
CD4+ T cells are generally accepted as the primary source of IL-17A and IL-17F. C. albicans-responsive 
CD4+ T cells belonging preferentially to the Th17 subset are found in the circulation of healthy 
individuals that have been exposed to C. albicans [46,47]. Consistent with a protective role of these cells 
in antifungal immunity, defects in T cells and more specifically in Th17 cells are a predisposing factor 
for mucocutaneous candidiasis (see above). In experimentally-infected mice, C. albicans-specific Th17 
cells develop in the draining lymph nodes within four to seven days after onset of infection [48,49]. A 
significant proportion of these cells recognizes a conserved antigenic epitope contained in the important 
fungal virulence factors agglutinin-like sequence (ALS) 1 and ALS3 [48]. A fraction of C. albicans-specific 
Th17 cells in humans also reacts towards the same epitope [48]. Differentiation of C. albicans-specific 
T cells into IL-17-secreting cells depends on C-type receptor signaling that acts through the tyrosine 
kinase Syk and the adaptor CARD9 and leads to the production of Th17-inducing cytokines, such as  
IL-6, IL-1β and IL-23, by antigen-presenting cells (APCs) [50,51]. Fungal determinants activating this 
pathway are thus critical for the T cell fate decision. However, tissue-specific factors of the host may 
also contribute, because in response to systemic infection, C. albicans-specific T cells differentiate 
primarily into IFN-γ-secreting Th1 and to a lesser degree into Th17 cells [52]. The tissue-specific 
regulation of T cell differentiation is likely related to the distinct distribution of different types of APCs 
in different tissues. Langerhans cells are a prominent DC population in the skin [53], and they were 
shown to drive the induction of the Th17 response during cutaneous candidiasis, while being dispensable 
for the T cell response to C. albicans in the oral mucosa, where they are rare (Trautwein-Weidner, 
Gladiator and LeibundGut-Landmann, unpublished). The DC compartments regulating Th cell priming 
during systemic candidiasis have not been investigated to our knowledge, but they are most likely 
distinct from those acting in barrier tissues. 
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Similar to the human situation, C. albicans-specific Th17 cells in infected mice form memory that 
remains stable over time, also after fungal elimination, and they mediate a slightly accelerated fungal 
clearance during re-infection via the cutaneous or the oral route [49,52]. In CD4-deficient mice, CD8+ 
T cells provide an alternative source of IL-17A in response to the fungus and functionally compensate the 
lack of Th17 cells [49], although these cells are no major players in this model if CD4+ T cells are present. 
The experimental infection of mice with C. albicans is acute, and the fungus is usually controlled 
rapidly in the presence of an intact IL-17 pathway. This indicates that IL-17 acts before Th17 are primed 
and capable of providing the cytokine. Indeed, IL-17A and IL-17F expression in the infected tissue is 
induced rapidly after infection [54], suggesting that the relevant source of IL-17 for fungal control is 
produced by innate and not by adaptive cells. RAG-deficient mice lacking T and B cells show a delay 
in fungal control during oropharyngeal candidiasis (OPC) [54,55], suggesting that RAG-dependent cells 
contribute to the acute response to the fungus. IL-17 expression by TCRαβ+ or TCRγδ+ lymphocytes 
one day post-infection was recently demonstrated by means of a fate reporter mouse in which an 
eYFP reporter irreversibly marks all cells with a history of IL-17A promoter activity [55]. Although 
RAG-deficient animals have a delayed fungal clearance, they do eventually control the infection and 
regain their initial body weight [54]. However, depletion of IL-17A and IL-17F in RAG-deficient mice 
completely abolishes their ability to control the body weight and the fungal burden [54], providing evidence 
for a RAG-independent source of IL-17 cytokines during experimental OPC. Innate IL-17-producing cells 
in the oral mucosa of RAG-deficient animals have been identified as CD90+ cells, consistent with them 
being innate lymphoid cells (ILCs) [54]. No evidence has been found for neutrophils contributing to the 
IL-17 response during mucocutaneous candidiasis in mice [56], although these cells may respond to 
autocrine IL-17A in some situations, and they appear to act as an important source of IL-17A in other types 
of fungal infections [57]. 
The existence of at least three different cellular sources of innate IL-17 during OPC illustrates the 
robustness of the innate immune system. While the absence of individual subsets of IL-17 secreting 
cells, as is the case in TCRβ-/- or TCRδ-/- mice, has no impact on susceptibility [54,55], the lack of both 
TCRαβ+ and TCRγδ+ T cells (as in RAG-deficient mice) causes some delay in fungal control and finally 
the absence of all lymphocytes and ILCs, as in RAG-deficient animals depleted of CD90+ cells or in 
RAG-Il2rg-deficient mice, resulting in a complete disability to control the fungus, similarly to the 
situation of IL-17 pathway deficiency [54]. The relative contribution of individual IL-17 producing cell 
subsets may be context dependent. During cutaneous candidiasis, TCRγδ+ T cells in the skin may 
represent the dominant source of IL-17 [58,59], similar to the situation in the psoriatic skin [60]. 
Human data and results obtained from mouse models of OPC and cutaneous candidiasis suggest 
that IL-17A and IL-17F are the predominant IL-17 family of cytokines for the protection against  
C. albicans [29,31,54,61–64]. IL-17A and IL-17F are co-expressed by Th17 cells and innate IL-17 
producers (Gladiator, Sparber and LeibundGut-Landmann, unpublished), and they act in a partially 
redundant manner [54]. In addition to IL-17A and IL-17F, the related cytokine IL-17C is also 
strongly induced during OPC [62,64], and consistent with the notion that IL-17C is produced by 
non-hematopoietic cells [65,66], the regulation of IL-17C secretion is RORγt independent in the oral 
mucosa [62]. However, IL-17C and the IL-17C-specific receptor subunit IL-17RE are dispensable for 
host defense against C. albicans, even in the absence of IL-17A and IL-17F [62], excluding redundancy 
between IL-17C and the functionally most closely-related IL-17 family of cytokines. 
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4. Mechanism of Action of IL-17 during CMC 
Research on IL-17 biology performed in recent years focused primarily on the identification and 
characterization of IL-17A- and IL-17F-producing cells, while much less effort was put into addressing 
the functional consequences of IL-17 signaling in biologically-relevant systems. Early studies attributed 
neutrophils a key role in IL-17-mediated responses. Many IL-17 target genes are linked to neutrophil 
trafficking [67,68], and forced expression of IL-17A can result in massive neutrophilia, while disruption 
of the IL-17 pathway can cause defects in the neutrophil response [69–74]. IL-17 signaling is thought to 
target mainly the non-hematopoietic compartment and epithelial cells, as well as fibroblasts expressing 
relevant target genes [75,76]. 
Neutrophils play an essential role during acute mucosal defense against C. albicans, in particular by 
preventing fungal dissemination [62,77]. Genes involved in neutrophil mobilization and trafficking, such 
as Csf3, Cxcl1 and Cxcl5, are induced during OPC in an IL-17RA-dependent manner [78]. Surprisingly, 
however, disruption of the IL-17 pathway does not affect the neutrophil response during OPC: neutrophil 
infiltration to the infected tissue, their localization in proximity to invading fungi and their candidacidal 
activity are not altered in IL-17RA- and IL-17RC-deficient mice [62], indicating that neutrophils act 
independently of IL-17 in the oral mucosa. Similar results were reported from an experimental model of 
psoriasis, where neutrophil recruitment to the skin was also uncoupled from the IL-17 pathway [76,79]. 
The link between IL-17 and neutrophils may thus strongly depend on the tissue environment, consistent 
with the notion that most situations, in which the IL-17 pathway was described to affect neutrophil 
recruitment, were observed in the context of pulmonary infections [69–74]. 
Another group of IL-17 target genes induced during OPC are antimicrobial peptides (AMPs), including 
S100A8 and S100A9 (which together form the heterodimeric complex calprotectin), β-defensin 3 and 
lipocalin 2 [78]. These agents were shown to display direct fungicidal activity through membrane 
depolarization and permeabilization [80] or to act by depriving the fungus of essential metal  
ions [81–83]. Besides their microbicidal activity, many AMPs exhibit additional functions by acting 
themselves as chemoattractants for a variety of innate immune cells or by stimulating other cells to 
secrete cytokines. In this context, β-defensin-1 was recently proposed to regulate IL-17A production 
during OPC and may thus act upstream of IL-17 [84]. Consistent with a critical role in mucosal host 
defense to C. albicans, β-defensin-1- and S100A9-deficient mice are impaired in fungal clearance [84]. 
However, their defect in controlling the fungus is not drastic (compared to the high susceptibility of  
IL-17RA- or IL-17RC-deficient mice), suggesting a considerable degree of redundancy between different 
AMPs. Interestingly, lipocalin 2 is fully dispensable for immunity to OPC, despite its very pronounced 
IL-17-dependent transcriptional regulation during infection [85]. Adding to the complexity of the 
biology of AMPs, many of them are expressed by different cell types that are differentially regulated 
during infection. IL-17-depdendent regulation of AMPs is restricted to the de novo synthesis in epithelial 
cells, while neutrophil-derived AMPs are preformed and released from granules or the cytoplasm upon 
neutrophil activation [62], in some instances in the context of NETosis [86]. Given the high degree of 
redundancy between different AMPs and their complex and differential regulation in multiple cell types, 
the relevant effector molecules mediating IL-17-dependent immunity to C. albicans still remain unclear. 
Besides antimicrobial molecules with direct fungicidal activities, IL-17-regulated factors controlling 
tissue regeneration and repair may also contribute. 
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In absence of a functional IL-17 pathway, experimental oral infection with C. albicans causes 
persistent colonization of the oral mucosa. The fungal burden remains high over time with fungal hyphae 
restricted to the epithelium without dissemination to deeper tissues or the circulation [62,78], indicating 
that some barrier functions are maintained in the absence of IL-17 signaling. Gradual reduction of the 
inflammatory response to C. albicans with/despite the persistence of high fungal loads [62] suggests that 
immune regulatory factors may come into play to control immunopathology and prevent overt 
inflammation in the infected tissue at the cost of preventing the clearance of the fungus. Future work is 
needed to identify the factors responsible for the equilibrium between fungal persistence and fungal 
control during OPC in IL-17-deficient hosts. 
5. The Role of IL-17 in Vulvovaginal Candidiasis 
Vulvovaginal candidiasis (VVC) is the most common manifestation of C. albicans infection, 
affecting ~75% of healthy women worldwide during their childbearing age [7]. Antibiotic treatment 
frequently increases vaginal C. albicans colonization and development of symptomatic VVC [87,88], 
suggesting that alterations in the vaginal microbiota may lead to the dysregulation of the antifungal 
resistance in the vaginal mucosa. However, the specific immune factors responsible for these changes 
are unknown, and it remains unclear whether IL-17 immunity is involved. CMC patients with mutations 
in IL-17F and other genes associated with the IL-17 pathway display symptoms of VVC [30,35,42,89] 
(in addition to oral candidiasis, as discussed above), but whether the disruption of the IL-17 pathway is 
a direct cause for VVC or rather an indirect effect due to the general increase in fungal colonization in 
these patients is unclear. 
Data from animal models on the role of IL-17 during VVC remain sparse and are controversial. While 
one group reported that IL-17A and Th17 cells enhance protection [90], data from another group suggest 
that fungal control and the calprotectin- and neutrophil-mediated immunopathogenic inflammatory 
response during experimental VVC is independent of the IL-17 pathway [91]. Future research will be 
necessary to establish the mechanisms regulating fungal growth and immunopathogenesis during VVC 
in more detail. 
6. The Role of IL-17 in Systemic Candidiasis 
The very first link between IL-17 and fungal infections was provided when Huang et al. infected 
IL-17RA-deficient mice with C. albicans via the intravenous route and observed that they rapidly 
succumbed from infection and were unable to control the fungus in the infected kidney [92]. This was 
well before the discovery of Th17 cells and the first description of polymorphisms in IL-17-related genes 
associated with CMC. The critical role of the IL-17 pathway in host defense against systemic C. albicans 
infection was confirmed recently [64,93]. Importantly, the mechanism of IL-17-mediated protection 
against disseminated infection differs greatly from IL-17 immunity in barrier tissues [93]. Expression of 
IL-17A and IL-17F was only weakly induced, and antibody-mediated blockage of the cytokines or their 
receptor had only a mild effect on innate fungal control, pointing to a developmental disorder in 
IL-17RA-deficient animals that affects systemic protection from C. albicans infection. The defect was 
mapped to natural killer cells, and supplementing the dysfunctional NK cell compartment of IL-17RA-deficient 
mice with wild-type NK cells was sufficient to correct for the inability of the mice to control C. albicans. 
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Antifungal defense of NK cells was found to act via a previously unrecognized mechanism: NK 
cell-derived granulocyte-macrophage colony-stimulating factor (GM-CSF), which is induced in 
response to Syk-dependent fungal recognition by CD11c+ DCs, promotes that antimicrobial activity of 
neutrophils [93,94]. 
The link between the IL-17 pathway and NK cells provides an unexpected mechanism of how 
IL-17A and IL-17 regulate protection from systemic infection with C. albicans. Given the broad and 
profound defect of IL-17RA- and IL-17RC-deficient NK cells in cytokine production and cytotoxicity [48], 
which resembles unlicensed NK cells, it can be speculated that its consequences reach beyond 
anti-Candida immunity, but may also be relevant for immunity against other fungi, as well as bacteria, 
viruses and possibly tumors. Future research will provide details about the molecular mechanism 
of IL-17-dependent NK cell function in mice and explore the relevance of these finding for NK 
cell-mediated immunity in humans. 
7. Conclusions 
Exciting discoveries of primary immunodeficiencies in CMC patients have enhanced our understanding 
of the pathophysiology of the disease and taught an important lesson about the physiological role of  
IL-17 in mucosal host protection. Previous studies have focused on the analysis of peripheral blood cells 
from these patients, but tissue-specific approaches will be necessary in the future to gain new insights 
into the IL-17-mediated immune control at different mucosal surfaces at the site of infection. However, 
such advances remain difficult given the small number of patients identified, many of which are children. 
Much of our current knowledge on the cellular and molecular regulation of IL-17 and its protective 
mechanisms against C. albicans has been gained from experimental mouse models that provide a 
valuable tool for studying antifungal immunity in vivo and in a tissue-specific manner. To what extent 
these results obtained in model animals are comparable to the human situation remains to be determined. 
An important limitation of the mouse models lies in the fact that mice are C. albicans-naive. Infecting 
mice with laboratory strains of C. albicans via the oral, vaginal or cutaneous routes induces an acute 
infection that is rapidly cleared by the innate immune system in immunocompetent hosts. To evaluate 
the mechanism of IL-17-mediated defense during chronic infection as seen in patients with CMC, 
modified versions of the mouse models should be developed to better mimic the situation in humans. 
This, together with broader studies in patients, will be critical for gaining a more detailed mechanistic 
understanding of the protective principles that may eventually be targeted in the clinic for improving 
patient outcome. 
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